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Abstract: Since their discovery in the 1950s interferons have been the scope of investigation 
in many diseases as therapeutic as well as pathogenetic factors. We know they have immune 
stimulatory and immune regulatory effects. This apparently counter-intuitive mechanism can 
be summarized as immunomodulatory action and seems to be very effective in a number of 
ocular inflammatory diseases. We review the current knowledge of interferons in immunity and 
autoimmunity and show their use in clinical ophthalmologic practice.
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What are interferons?
Interferons (IFNs) were discovered in 19571 as natural antiviral substances produced 
during viral infection and were characterized for their ability to ‘interfere’ with viral 
replication, reduce cell proliferation, and alter immunity. They have received atten-
tion because of their diverse effects, influencing both innate and adaptive immune 
responses;2 thus they are involved as well in defense against viral infections, tumor 
growth, and tolerance induction as well suspected inducers of autoimmune disease, 
such as sarcoidosis.3,4 At the same time they have been used successfully as treatment 
for autoimmune diseases such as multiple sclerosis.5 Thus in autoimmunity IFNs appear 
as double agents, involved in both supportive and suppressive action.
The different IFNs have been classified into type I, with the large group of IFN-α 
isotypes and IFN-β as the most immunologically relevant, and type II, with the single 
member IFN-γ, based on their amino acid composition and biologic properties. Type I 
IFNs share a common receptor, the IFN-α/β receptor, IFNAR, whereas IFN-γ as the 
only representative of type II IFNs binds to a different receptor, IFNGR.
There is a single IFN-β, while there are at least 13 different IFN-α isotypes. 
Evidence suggests that they have distinct functions. Their expression seems to depend 
on the stimulating agent and the cell type.6
In addressing the role of IFN-α/β in autoimmunity, it is important to recognize that 
in addition to direct action their effect may be mediated by synergistic or antagonistic 
interactions with other cytokines. As the clinical experience is limited mainly to type I 
IFNs, for sake of clarity and space restrictions we concentrate on these.
Virtually any cell can produce type I IFNs, but antigen presenting cells, especially 
plasmacytoid dendritic cells, are the main producers of type I IFNs, already at early 
stages of the immune response. Thus, type I IFNs, especially IFN-α, may be the pivotal 
cytokines linking the innate with the adaptive immune system. Low levels of type I Clinical Ophthalmology 2009:3 560
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IFNs seem to be prerequisites for the upregulation of type I 
IFNs as a reaction to viral infection and subsequent induc-
tion of IFN-γ production. This finally leads to the induction 
and maintenance of T-helper type 1 cells, CD8+ cytotoxic 
T cells, and natural killer cells that fight the viral intrusion. 
In contrast, type I IFNs have also been shown to exert an 
antiproliferative and proapoptotic effect on T cells. Another 
IFN effect is the development of tolerance-promoting regu-
latory T cells. Equally there has been a positive as well as 
an inhibitory effect described on B-cell development and 
survival.6,7
IFNs also have been shown to be involved in the patho-
genesis of several autoimmune diseases as systemic lupus or 
type I diabetes.8,9 Systemic lupus is a highly heterogeneous, 
multiorgan disorder primarily afflicting women and is 
characterized by the production of diverse autoantibodies, 
predominantly against nucleosomal and spliceosomal 
antigens. Type I IFNs, central to both innate and adaptive 
immunity, have received particular attention for their 
role in the development of autoimmune responses, and a 
preponderance of evidence supports their disease-promoting 
activity in lupus (reviewed in).8,10 In humans with active 
disease, levels of IFN-α are increased in serum and affected 
tissues.
Supposed mechanisms of action
IFNs are thought to have immunomodulatory effects rather 
than immunosuppressive mode of action. This is supported 
by insights from animal models of uveitis (see below), but 
also from studies in humans that were treated with IFNs.
IFN in animal models
Experimental autoimmune encephalomyelitis (EAE) is a 
well-established rodent model of CNS-specific inflammatory 
disease and is known to be the best animal model for studying 
the etiology and pathogenesis of encephalomyelitis dissemi-
nata (ED). It is mediated by T cells and results in progressive 
demyelination and paralysis.
There are several subtypes of T cells in the immune 
system. They are distinguished by their surface receptors 
and cytokine repertoire and their differentiation is influenced 
by the cytokines in their environment. For quite some 
time the (dis)balance of TH1 (autoagressive) and Th2 
(downregulating) CD4+ T cells was thought to induce 
autoimmunity. Newer research showed the existence of 
several more T cell subtypes, as the CD25+, FOXP3+ T 
“regulatory” T cells, or so-called Th17, IL-17 producing, 
possibly autoimmunity supporting cells.11
As in ED, EAE is characterized by a breakdown of 
the blood–brain barrier. The inflammatory response is 
characterized by T cell infiltrates located around vessels of 
the CNS white matter, by activation of local microglia and 
astrocytes, and in the most severe cases it may be eventually 
followed by demyelination. Anterior uveitis (AU) has been 
found to coincide with EAE in rabbits, monkeys, in the 
Lewis rat,12,13 and in mice.14,15 The encephalitogenic T cells 
are specific for the antigen myelin basic protein (MBP), 
which is a component of the myelinated sheath surrounding 
nerve bundles. These myelinated nerve bundles are abundant 
in the spinal cord and in the iris; thus this “autoantigen” 
is located at sites of inflammation. In the rodent models of 
EAE, AU generally persists after the paralysis has subsided. 
EAE and AU can be induced actively by immunizing with 
MBP in the presence of adjuvant, or passively by using 
adoptive transfer of MBP-specific T cells that have been 
generated against the whole antigen or encephalogenic 
peptides. Mice deficient in IFN-β showed augmented and 
chronic EAE.16 Histopathological investigations of CNS in 
the effector phase revealed an extensive microglia activation 
and TNF-α production in IFN-β KO mice; this was virtu-
ally absent in wildtype littermates. This coincided with an 
increase in effector functions of  T cells in IFN-β KO mice. 
The authors suggested that that the lack of IFN-β leads to 
persistent activation of residual antigen presenting cells, 
which results in prolonged inflammation and extensive 
demyelination. Another more recent study used EAE as 
a model to investigate the role of the TRIF-dependent 
IFN induction pathway of the innate immune system 
in the regulation of autoimmune inflammation, show-
ing that Th-17 mediated autoimmune inflammation was 
negatively regulated via IFN-induced IL-27 production in 
macrophages.17
Another mouse model of intraocular inflammation is 
experimental autoimmune uveitis (EAU), which is induced 
by interphotoreceptor retinoid-binding protein (IRBP) in rats 
or mice. EAU can be mitigated or prevented by IFN-α2a or -β 
treatment, in the animal model even an oral application was 
shown to be effective.18–21
IFN in human disease
Generally type I IFNs have been shown to have multiple 
immunostimulatory as well as immunosuppressive 
effects.6,22 On the one hand, a shift towards Th1 T cell 
response and related cytokines has been shown, an increase 
in MHC class I expression and cellular adhesion molecules, 
an increase in cytotoxicity of T cells, and especially Clinical Ophthalmology 2009:3 561
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increase in numbers as well as in activity of NK cells.23 
This is helpful to eliminate foreign antigen and would 
explain the anti-viral and anti-tumor effect, but would at 
the same time indicate an immune-stimulatory capacity 
that is promoting autoimmunity rather than treating it. 
IFN is used in treatment of melanoma, and especially 
in responders autoimmune disease has been described.24 
The development of autoimmunity was higher in the 
extended treatment group. IFNs are also involved in the 
development of autoimmune diseases as diabetes type I.9 
Thus, the immunoregulatory effects of IFNs are harder to 
grasp. Especially in Behçet´s disease (BD) investigations 
have been undertaken: Treusch and colleagues have shown 
that numbers of g-d T cells are normalized25 and soluble 
TNF receptor increases.26 These apparently incompatible 
stimulatory versus regulatory effects (see Figure 1) were 
reconciled by more recent results from human studies 
showing an upregulation of  T regulatory cells in patients 
with BD treated with IFN.27 Wang and colleagues showed 
that IFN-α2b upregulates STAT5 and downregulates 
STAT3, in conjunction with upregulation of Treg and 
inhibition of IL-17-expressing lymphocytes in melanoma 
tissues.28 Similarly, it has been shown that IFN-β1a inhibits 
the secretion of Th17-polarizing cytokines in human 
dendritic cells via TLR7 up-regulation.29 The discovery 
of the Th17 cell lineage marked a new era in the studies 
of the autoimmune response, as it resolved many contro-
versial findings not compatible with the Th1 paradigm of 
autoimmune response.30 In summary the influence of type I 
IFNs on the immune system is still not fully elucidated, but 
seems to be a very complex web of dosage, timing, and 
type of cell involved.
A number of clinical trials and case series have been 
published on systemic treatment with type I IFNs in uveitis. 
Table 1 lists these in detail. The mode of administration 
generally is subcutaneous. Intravitreal application has been 
tried in only 2 patients with advanced neovascular age-related 
macular degeneration with little response and was not 
pursued any further due to a reversible reduction in the light 
response on electroretinography after 1 month.31
Behçet’s disease (BD)
BD is a multisystem disorder that can affect basically 
all organs. It is common in countries along the old silk 
route from Turkey and Japan. Uveitis in a patient with BD 
is accompanied by severe inflammation with occlusive 
vasculitis that can lead to visual impairment. Therefore, 
many drugs have been investigated for their potential in 
preventing ocular recurrences in patients with BD, including 
azathioprine,32 cyclosporine A,33 and infliximab.34
As a viral pathogenesis is thought to play a role in the 
pathogenesis of BD, IFN-α was introduced in 1986 for its 
antiviral activity, with encouraging results.35 In 1994 Feron 
et al36 used IFN-α for the first time in patients with ocular BD. 
Kotter et al37 have published the widest experience in treating 
patients with BD with IFN-α. They published an open, 
noncomparative prospective study including 50 subjects. 
In this study, the drug was administered initially at a dose 
Figure 1 interferons: immunostimulatory vs immunoregulatory effects.
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of 6 million units daily, with dose and frequency adjusted 
depending on the clinical response. A response rate of 92% 
was reported, with significant improvements in both visual 
acuity and posterior uveitis score. More than one third of 
patients were off treatment and disease-free at an average 
of 2.5 years. The IFN treatment was also beneficial for 
extraocular manifestations of BD, although less so for oral 
ulcerations.
Alpsoy and colleagues38 performed a randomized, 
placebo-controlled, double-blind trial showing IFN-α2a to be 
superior to placebo in oral and genital ulcer reduction as well 
as in ocular flare reduction. The study included 50 patients, 
of whom nine had ocular involvement. Other groups have 
published case series supporting therapeutic effects of IFN-α 
in this subtype of uveitis.39–43
There have been 2 meta-analysis of the literature 
performed.44,45 The first analysis included 32 original reports 
and 4 selected abstracts. Systemic IFN-α was administered 
to 338 patients, including 182 with acute ocular disease. 
Eighty-six percent of the patients with mucocutaneous 
symptoms, 96% with arthritis, and 94% with uveitis 
exhibited a partial or complete response. Higher IFN doses 
were more effective than low-dose regimens. Long-term 
remissions seem to be associated with higher doses, but 
not longer duration of treatment. IFN-α2a apparently was 
superior to IFN-α2b.
The second included 22 studies with 144 participants 
(some  participants  were  shared  between  studies). 
Fourteen studies (70 participants) reviewed treatment with 
IFN-α2a and 8 studies (74 participants) reviewed treatment 
with IFN-α2b. Seventy-four percent of patients with 
mucocutaneous manifestations, 95% of patients with uveitis, 
and 93% of patients with arthropathy/arthritis exhibited a 
partial or complete response. IFN-α2a regimens were more 
effective than IFN-α2b ones on mucocutaneous (47% versus 
7% complete response) and ocular (67% versus 8% complete 
response; P  0.001) manifestations.
Bodaghi and colleagues presented a retrospective evalua-
tion of 45 patients treated with IFN-α2a.46 About half of the 
patients had BD. Especially in these patients, the treatment 
was effective (82.6%), but it was also judged effective in 
59% of the patients with other types of uveitis. Subsequently, 
it was possible to significantly reduce oral prednisone in 
both groups. The same group published their results for 
32 patients with BD and IFN in 200847 and also for pediatric 
BD.48 In contrast to the Koetter group, these authors started 
IFN treatment together with an iv methylprednisolone pulse 
and subsequent oral taper, reaching a final mean of 7 mg 
of oral prednisone/day. Colchicine was allowed as adjunct 
treatment. Another group recently published their long-term 
results on 45 patients with BD and also started with 100 mg 
of prednisone and subsequent rapid taper down to 10 mg in 
Table 1 Systemic interferon treatment in ocular inflammatory disease 
Author, Year Type of study n Systemic  
disease (n)
Uveitis (n) Dose (mio IU) Interval Improvement 
(of uveitis) %
Interferon-α
Deuter 200964 retr. CS 24 None 24  3–6  Daily  62.5–87.5a
Krause 200843 retr. CS 45 BD 45 3–9 3/week 73–92b 
Gueudry 200847 retr. CS 32 BD 32 3 3/week 82.1c 
Bodaghi 200746 retr. CS 45 BD (23)/ 
other (22) 
45  3  3/week  82.6 
59 
Guillaume-Czitrom  
200748
retr. CS 7 Pediatric BD 7 1.5–3 3/week 71.4 
Plskova 200765 Pros. CS  12 BD (2)/none (10) 12 6 Daily 83 “clinical response”
Tugal-Tutkun 200642 retr. CS 44 BD 44 3–6 Daily 36.4–91d 
Kotter 200444 retr. Meta-analysis 338 BD 182 variable variable 94
Kotter 200437 Pros. open label 50 BD  50  6–3  Daily to 
3/week 
92 
Alpsoy 200238 Pros., controlled 50 BD  9  6 or placebo  3/week 83 versus 33 
Interferon-β
Becker 200556  retr. CS 13  Multiple sclerosis  13  22/44 µg sc (10) 
30 mg im (3) 
3/week or 
1 weekly 
71 
areduction in cystoid macular edema incl. partial response; b92% any improvement, 78% no recurrence, 73% discontinued pred; c82.1% (no more relapses), 87.5% (+ partial 
response); d36.4% (no more relapses), 91% (+ partial response)
Abbreviations: mio iU, million international units; sc, subcutaneously; im, intramuscularly; BD, Behçet´s disease; CS, case series.Clinical Ophthalmology 2009:3 563
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2 weeks.43 See also below for controversial opinions about 
additional immunosuppressive treatment.
Several case series about the effective use of IFN-α 
inhibitors in BD have been published (for a review see49).
EULAR  recommendations  say  to  introduce  either 
cyclosporine or infliximab as a second line agent in 
refractory eye involvement; alternatively IFN-α can be 
used.50 So far no direct comparison of IFN-α inhibitors and 
IFNs or other immunosuppressive agents and IFN have 
been performed, but a multicentric national trial is currently 
ongoing comparing IFN versus cyclosporine (INCYTOB, 
see clinicaltrials.gov).
encephalomyelitis disseminata  
(multiple sclerosis)
Intermediate uveitis is the most frequent form of ED-associated 
uveitis. Anterior uveitis is rare in patients with ED, but if it 
occurs is of the granulomatous subtype.51,52 A sign of inter-
mediate uveitis are snowbanks and snowballs. Especially in 
intermediate uveitis accompanying ED, snowbanks and conti-
nous retinal periphlebitis in combination seem to be typical.53,54 
In patients with this type of uveitis, secondary changes like 
the formation of cystoid macular edema (CME) or occlusive 
vasculitis with vasoproliferations can develop (Figure 1), 
which may be complicated by retinal detachments or vitreous 
hemorrhage.55 Especially macular edema with subsequent 
epiretinal membrane formation is a challenge and a threat to 
visual prognosis.
There is increasing evidence that IFN is very effective in 
treatment of uveitis associated with ED, especially the accom-
panying macular edema. We used type 1 IFNs to treat uveitis 
associated with multiple sclerosis that was refractory to 
corticosteroid treatment in a retrospective, multicenter obser-
vational case series. Thirteen patients (8 female, 5 male) with 
proven multiple sclerosis and associated uveitis in 25 eyes 
from 5 uveitis centers were treated with IFN-β1a. Visual 
acuity improved in 17 eyes (71%), 5 did not change (21%), 
and 2 eyes deteriorated (8%) because of development of 
cataract. CME resolved after or during IFN treatment in 82% 
of the eyes. Side effects were noted in three patients (elevation 
of liver enzymes in 1 patient, depression in 1, and joint pain 
in 1). At the last visit, 9 patients (69%) had discontinued 
systemic corticosteroids; 3 were taking 10 mg of prednisone 
or less. Treatment of multiple sclerosis-associated uveitis 
with IFN appeared to have beneficial effects on visual acuity, 
intraocular inflammation activity, and the presence of CME 
in this study.56,57 First results of a randomized, controlled, 
clinical trial have been presented at the Association for 
Research in Vision and Ophthalmology (ARVO) meeting, 
indicating superiority of IFN over methotrexate in patients 
with intermediate uveitis with or without ED.58
Inflammatory macular edema
Macular edema is a major cause of vision loss in patients with 
uveitis.59 Diverse treatments are in use, which include peri-
ocular or intravitreal corticosteroid injections, systemic corti-
costeroids, acetazolamide, immunosuppressive medications, 
octreotides and even intravitreal bevacizumab injections.60–63 
None of these medications has been tested in a randomized, 
controlled, clinical trial.
Deuter et al57 were the first to show a positive effect of 
IFN-α on uveitic CME in a prospective case series. The 
authors treated 8 patients (2 male, 6 female) with IFN-α2a 
at an initial dosage of 3 or 6 million units daily, depending 
on body weight. All patients had inactive primary uveitis 
with CME that had not responded to systemic corticosteroids 
and acetazolamide previously. In seven patients, a response 
to IFN-α2a was seen within 3 days, and CME completely 
disappeared after 2 to 4 weeks in all 13 eyes in these 
patients. In the nonresponder, anti-IFN-α2a antibodies were 
discovered. Recently, the authors published their experiences 
in the long-term treatment of 24 patients.64
Other uveitis subtypes
Plskova65 and colleagues published their experiences with 
IFN-alpha 2b in severe posterior or panuveitis. Two of their 
patients were diagnosed with BD, 1 sympathetic ophthalmia, 
the rest were idiopathic. A positive clinical response was 
observed in 83% of their patients. Bodaghi and coauthors 
published a retrospective evaluation of 45 patients treated 
with IFN-α2a.46 About half of the patients had BD, but 22 
had other forms of uveitis. In 59% of these patients, the 
treatment was judged effective.
Specifics of IFN treatment
Types of iFN available for treatment
Three different IFN-β drugs (Avonex® [β1a], Rebif  ® [β1a], 
Betaseron® [β1b]) and 2 IFN-α drugs (Intron A® [IFN-α2b], 
Roferon® [IFN-α2a]) are available.
iFN ± other immunosuppressive 
treatment?
Owing  to  the  particular  mode  of  action  of  IFNs 
(immunomodulatory rather than immunosuppressive), it is 
thought that IFNs need an unsuppressed immune system. Clinical Ophthalmology 2009:3 564
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In 200666 we wrote in a similar review on IFNs “Therefore, 
it is recommended to use additional corticosteroids only 
in low doses. The concurrent use of immunosuppressives 
should be avoided during IFN treatment.” This was proposed 
especially by Kotter and coworkers previously.67 They based 
this recommendation on their clinical experience,68 backed 
up by the rationale that the activity of NFκB is reduced by 
glucocorticoids. NFκB is a transcription factor that is thought 
to regulate the sensitivity of cells toward IFN-mediated antiviral 
activity69 and is itself activated by IFN in a signaling pathway 
that protects cells against apoptosis.70 Recently, several authors/
studies put this paradigm to a test: Gueudry et al47 treated BD 
uveitis with initial methylprednisolone pulse and IFN-α and 
never aimed to taper corticosteroids completely. In a case 
series of 2 patients with BD and uveitis Harmuryudan et al71 
combined IFN and azathioprine with good results. As can be 
seen in Table 1, different groups have used IFNs in combina-
tion with immunosuppressive agents. There is also increasing 
evidence from the ED literature that adding corticosteroids 
or other immunosuppressives to IFN reduces formation of 
neutralizing antibodies and thus improves clinical response.72 
Especially one pilot study could show this for a combination 
of IFN-β1a and mycophenolate mofetil (Cellcept®),73 clinical 
trials addressing this topic are currently undertaken.
Apparently this is a preventive measure and does not work 
once neutralizing antibodies have been formed.74
Management of iFN therapy
A close collaboration between other specialists and 
ophthalmologists is helpful to optimally direct IFN treatment. 
It is necessary to perform an exact medical history before 
starting IFN therapy focusing on autoimmune diseases (besides 
uveitis), impaired thyroid or liver function, and previous 
or current depressive disorders in particular antecedents of 
suicidal ideation. Patients should be informed of the most 
frequent adverse reactions associated with IFN therapy to 
improve compliance.
Secondary effects
Common side effects of IFN include injection-site reactions, 
flu-like symptoms (fever, headache, myalgia, arthralgia, 
sweating, and fatigue), leukopenia, liver enzyme eleva-
tions, and alopecia. The flu-like symptoms can be alleviated 
by concomitant administration of paracetamol and seem 
to represent a good prognostic marker for a response to 
IFN treatment, as this may indicate the absence of pre-
existing anti-IFN autoantibodies. Usually, severity of these 
symptoms will decrease in the course of therapy. Patients 
with cardiac disease, such as angina, congestive heart failure, 
or arrhythmia, should be closely monitored for worsening of 
their clinical condition during initiation of therapy with IFNs 
as symptoms of the flu-like syndrome may prove stressful to 
patients with cardiac conditions.
Depression and suicidal intentions can occur during 
therapy with IFN independent of preexisting psychiatric 
disease.75 Patients treated with IFNs should be advised to 
immediately report any symptoms of depression and/or 
suicidal ideation to their prescribing physician.
IFN-α in combination with ribavirin treatment in hepatitis 
C infection has led to development of sarcoidosis in some 
patients.3 If this is due to HCV itself acting as an antigenic 
trigger for the development of sarcoidosis in susceptible 
patients, or the action of ribavirin in combination with IFN-α, 
or the latter alone is unknown so far. Of interest, no reports 
of IFN-β leading to sarcoidosis have been published so far, 
and no patients treated with IFN-α for other diseases such 
as BD have been diagnosed with sarcoidosis. Still, this may 
be due to the lower numbers in these cohorts.
Retinopathy (cottonwool spots and/or hemorrhages) 
has been reported as an ocular complication of hepatitis C 
treatment with IFN, with frequencies varying from 3.8% 
to 24% in studies, but generally with a good outcome.76–79 
There are also about 6 single case reports of multiple 
sclerosis-related IFN-associated retinopathy.80–82
IFN therapy may induce formation of autoantibodies 
and other immune-mediated diseases as auto-immune 
thyroiditis.24
Laboratory exams
Laboratory abnormalities are associated with the use of 
IFNs. Basic lab tests include complete and differential blood 
count, platelets, and liver enzymes (especially ALT). Lab 
tests should be repeated at months 1, 3, and 6 on therapy and 
periodically thereafter. Dose reduction of IFN therapy should 
be considered if ALT rises above 5 times the upper normal 
limit. Patients being treated with IFNs may occasionally 
develop new or worsening thyroid abnormalities. Thyroid 
function testing is recommended at baseline and if abnormal, 
every 6 to 12 months after initiation of therapy. If tests are 
normal at baseline, routine testing is not needed but should be 
performed if clinical findings of thyroid dysfunction appear 
(ref: Summary of Product Characteristics).
Conclusion
IFNs have been shown highly effective in the treatment of 
uveitis. Most data exist for IFN-α2a in BD, from 1 placebo Clinical Ophthalmology 2009:3 565
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controlled trial and 2 meta-analyses. IFN-α may be given for 
ocular BD not responsive to a first-line immunosuppressive, 
as per EULAR recommendations.50 Evidence is emerging 
for the use of IFN in the treatment of inflammatory macular 
edema, but final results from a prospective clinical trial are 
lacking.
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